🔥 BREAKING: THEMA KR7000100008 | Don't Miss This! 💥

Sie befinden sich hier: Startseite > Themen > KR7000100008?lang=en

Thema: KR7000100008

Yuhan, KR7000100008

Yuhan stock: Boehringer expands Korean healthcare partnership

Yuhan stock is in focus after Boehringer Ingelheim agreed to broaden their Korean healthcare partnership beyond pharmaceutical sales. New projects will target patient access and medical collaboration.

ad-hoc-news.de, heute 00:34 Uhr

Yuhan, KR7000100008

IBK cuts target for Yuhan stock to KRW 110,000

IBK cut its target from KRW 160,000 to KRW 110,000 on October 16, 2026. For Yuhan stock, the margin forecast is 5.4 percent.

ad-hoc-news.de, 19.10.26 03:20 Uhr

Yuhan, KR7000100008

Yuhan stock edges higher as investors digest latest results ...

Yuhan stock trades moderately higher on August 28, 2026, with investors weighing solid recent earnings against the company’s valuation and Korea pharma sector dynamics.

ad-hoc-news.de, 29.08.26 09:06 Uhr

Yuhan, KR7000100008

Yuhan Stock - analyst consensus and sector context on a ...

Yuhan stock trades without fresh corporate headlines today. With no new filings or major news investors turn to analyst estimates and the broader South Korean pharma sector ...

ad-hoc-news.de, 19.06.26 17:18 Uhr

Yuhan, KR7000100008

Yuhan Stock - Wednesday strategy and operations snapshot ...

Yuhan stock gets a Wednesday spotlight with an operational and strategy snapshot. With no fresh regulatory or earnings news today investors are weighing the Korean pharma ...

ad-hoc-news.de, 17.06.26 18:34 Uhr

Yuhan, KR7000100008

Yuhan Corp stock (KR7000100008): Korean pharma player in ...

Yuhan Corp draws investor interest as the Korean pharmaceutical group advances its pipeline and expands partnerships. What drives the business model and which revenue streams ...

ad-hoc-news.de, 08.06.26 15:17 Uhr

Yuhan, KR7000100008

Yuhan Corp stock (KR7000100008): South Korean pharma name ...

Yuhan Corp shares on the Korea Exchange traded broadly steady at the start of June while investors follow the South Korean drugmaker’s role in the fast-growing global obesity ...

ad-hoc-news.de, 01.06.26 03:48 Uhr

Yuhan, KR7000100008

Yuhan Corp stock (KR7000100008): R&D Day spin-off plans ...

Yuhan shares in South Korea trade in focus after the company used its May 28 R&D Day to outline a spin-off of its allergy drug candidate into a NewCo as part of a post-Lazertinib ...

ad-hoc-news.de, 29.05.26 03:41 Uhr

securities-and-exchange-7499697_1920.jpg - Foto: THN

Yuhan, KR7000100008

Yuhan Corp stock (KR7000100008): licensing deals and pipeline ...

Recent licensing activity and pipeline updates keep Yuhan Corp in focus for healthcare investors watching Asian drug developers with global partnerships.

ad-hoc-news.de, 21.05.26 19:23 Uhr

Yuhan, KR7000100008

Yuhan Corp stock (KR7000100008): Supreme Court tax ruling ...

Yuhan Corp is back in the spotlight after a Supreme Court ruling on tax exemption tied to a 2016 technology transfer from Genosco. The case matters for investors watching ...

ad-hoc-news.de, 19.05.26 07:33 Uhr

Thema: KR7000100008

Yuhan stock is in focus after Boehringer Ingelheim agreed to broaden their Korean healthcare partnership beyond pharmaceutical sales. New projects will target patient access and medical collaboration.

IBK cut its target from KRW 160,000 to KRW 110,000 on October 16, 2026. For Yuhan stock, the margin forecast is 5.4 percent.

Yuhan stock trades moderately higher on August 28, 2026, with investors weighing solid recent earnings against the company’s valuation and Korea pharma sector dynamics.

Yuhan stock trades without fresh corporate headlines today. With no new filings or major news investors turn to analyst estimates and the broader South Korean pharma sector ...

Yuhan stock gets a Wednesday spotlight with an operational and strategy snapshot. With no fresh regulatory or earnings news today investors are weighing the Korean pharma ...

Yuhan Corp draws investor interest as the Korean pharmaceutical group advances its pipeline and expands partnerships. What drives the business model and which revenue streams ...

Yuhan Corp shares on the Korea Exchange traded broadly steady at the start of June while investors follow the South Korean drugmaker’s role in the fast-growing global obesity ...

Yuhan shares in South Korea trade in focus after the company used its May 28 R&D Day to outline a spin-off of its allergy drug candidate into a NewCo as part of a post-Lazertinib ...

Recent licensing activity and pipeline updates keep Yuhan Corp in focus for healthcare investors watching Asian drug developers with global partnerships.

Yuhan Corp is back in the spotlight after a Supreme Court ruling on tax exemption tied to a 2016 technology transfer from Genosco. The case matters for investors watching ...

Aktienkurse

Nachrichten

Service

Kursinformationen